F S&P 500
5,341.25 +13.25 (+0.25%) F Dow Jones
39,732.00 -51.00 (-0.13%) F Nasdaq
18,873.50 +86.75 (+0.46%) E-mini Russell 2000 Index Futur
2,088.30 -0.80 (-0.04%) Petróleo
77.02 -0.55 (-0.71%) Oro
2,382.90 -10.00 (-0.42%)
Co-Diagnostics, Inc. (CODX)
Fuera de horario:
Co-Diagnostics, Inc.
2401 South Foothill Drive
Suite D
Salt Lake City, UT 84109
United States
(801) 438-1036
https://www.codiagnostics.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 155
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Dwight H. Egan | Chairman & CEO | 415.75k | N/D | 1953 |
| Mr. Brian L. Brown CPA | CFO & Company Secretary | 338.92k | N/D | 1976 |
| Mr. Richard David Abbott | President | N/D | N/D | 1972 |
| Dr. Brent C. Satterfield Ph.D. | Co-Founder & Member of Scientific Advisory Board | 237.5k | N/D | 1977 |
| Mr. David Nielsen | Chief Operating Officer | N/D | N/D | N/D |
| Mr. Dan Bohrer CPA | Vice President of Finance & Accounting | N/D | N/D | N/D |
| Mr. Christopher Thurston | Chief Technology Officer | N/D | N/D | N/D |
| Dr. Mark Poritz Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
| Mr. Andrew Benson | Head of Investor Relations | N/D | N/D | N/D |
| Dr. Mayuranki Almaula | Senior Vice President of Overseas Operations & Strategic Alliances | N/D | N/D | N/D |
Descripción
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Gestión corporativa
La calificación ISS Governance QuickScore de Co-Diagnostics, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 9; Junta: 10; Derechos del accionista: 5; Compensación: 8.
